Sotigalimab is a potent CD40 agonist that has been designed to reverse the systemic immune suppression that typically affects cancer patients, through the activation of several mechanisms of immune functionality. CD40 is a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Activation of CD40 initiates and amplifies a complex, multi-cellular immune response, bringing components of both immune systems to work in concert against cancer.
CD40 Plays a Central Role in the Immune Response Against Cancer
Sotigalimab is a humanized monoclonal antibody that binds CD40 with high affinity and activates antigen presenting cells (dendritic cells, monocytes and B cells) leading to stimulation of cancer-specific T-cell responses. As such, CD40 activation could play a fundamental role in tumor-specific immune activation.
Apexigen believes Sotigalimab has the potential to be a best-in-class CD40 agonistic antibody that can be used as a single agent and in combination with other immuno-oncology agents, targeted therapeutics, chemotherapies, vaccines and radiation therapy.
Apexigen has two additional immuno-oncology programs currently in preclinical development.
CD40 Agonistic Antibody Provides Critical Signals for T-cell Activation
CD40 agonistic antibody activates tumor-specific CD8+ T cells by enhancing antigen processing and presentation to T-cell, and providing co-stimulatory signals (CD80, CD86 and IL-12)
Apexigen is pioneering the great diversity of rabbit antibodies as a rich source for the discovery, generation and humanization of proprietary therapeutic monoclonal antibodies to address high-value disease targets. APXiMAB™, our proprietary antibody discovery platform, consists of the Company’s rabbit monoclonal antibody and Mutation Lineage Guided humanization technologies. Antibodies discovered using APXiMAB™ have demonstrated high affinity, high specificity and high stability. Apexigen is applying the diversity inherent to its discovery platform to produce best-in-class leads with the promise of superior attributes and improved safety profiles, and new classes of humanized antibodies against challenging and previously intractable targets.
APXiMAB™ has enabled Apexigen to build its own antibody pipeline focused on new immuno-oncology product candidates, as well as to form broad strategic partnerships with numerous pharmaceutical companies for programs that are outside of the Apexigen’s proprietary product focus.